A5024986231- Economic and Financial Impacts of Cancer
- COVID-19 and healthcare impacts
- Diversity and Career in Medicine
- Global Cancer Incidence and Screening
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Global Health Workforce Issues
- Advances in Oncology and Radiotherapy
- Acute Myeloid Leukemia Research
- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Ethics in Clinical Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Health Literacy and Information Accessibility
- Cardiac Structural Anomalies and Repair
- Breast Cancer Treatment Studies
- Prostate Cancer Treatment and Research
- Pericarditis and Cardiac Tamponade
- Nigella sativa pharmacological applications
- Hepatitis Viruses Studies and Epidemiology
- Actinomycetales infections and treatment
- Animal Virus Infections Studies
University of Minnesota
2023-2024
University of California, San Francisco
2019-2023
University of Minnesota Medical Center
2023
UNC Lineberger Comprehensive Cancer Center
2023
University of Minnesota System
2023
UCSF Helen Diller Family Comprehensive Cancer Center
2022
Mayo Clinic in Arizona
2017-2019
Mayo Clinic
2017-2018
University of Minnesota Rochester
2018
Yale University
2016
Compared with people living without HIV (PWOH), (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use ICIs in PWH cancer.
Abstract Introduction. T-DXd is FDA-approved for patients (pts) with hormone receptor positive (HR+) or HR- HER2-low (IHC 1+ 2+, ISH-) MBC and SG pts HR+/HER2- triple negative MBC. However, several outstanding questions impact the use of these drugs in clinic, including: 1) what efficacy safety agents real-world populations diverse pt characteristics not well represented pivotal phase III trials, 2) sequential treatment ADCs on agents. Methods. In this multicenter retrospective cohort study,...
Abstract A 27‐gene panel was used for next‐generation sequencing (NGS) in 179 patients (median age 73 years) with primary myelodysplastic syndromes (MDS); risk distribution according to the revised International Prognostic Scoring System (IPSS‐R) 11% very high, 18% 17% intermediate, 38% low and 16% low. At least one mutation/variant detected 147 (82%) patients; 23% harbored three or more mutations/variants. The most frequent mutations/variants included ASXL1 (30%), TET2 (25%), SF3B1 (20%),...
1083 Background: T-DXd and SG are both FDA-approved treatments for patients (pts) with HER2-low MBC, but little data exists on the sequential use of these ADCs. Methods: In this multicenter retrospective cohort study, we identified pts MBC treated sequentially in either order, or without intervening therapies (IntTx), at 5 academic centers between 2020-2023. We previously reported real-world progression free survival (rwPFS) overall (rwOS) by HR-status ADC sequence order. Here provide...
<p>Supplemental Figure 1. Age distributions from 2019 vs. 2021 American Community Survey (ACS) 2019-2021</p>
<p>Supplemental Table 1. Population counts per pandemic time period and absolute change in percentage of late-stage cancer diagnoses for Post-Shutdown #2 Post-Vaccine Rollout</p>
<div>AbstractBackground:<p>The COVID-19 pandemic and associated shutdowns disrupted healthcare access resulted in decreased cancer screenings. Cancer diagnosis delays have concerning downstream effects on late-stage cancer, especially for marginalized populations.</p>Methods:<p>The study population included 349,458 adults the California Registry diagnosed with between January 2019 December 2021, during which experienced two stay-at-home orders. We examined percentage...
We examined the influence of mutations and karyotype on conventional treatment response, specifically hematological improvement in anemia, primary myelodysplastic syndromes (MDS). Cytogenetic next generation sequencing (NGS)-derived mutation information was available 357 patients (median age 74 years; 70% males); revised international prognostic scoring system risk distribution very high 11%, 15%, intermediate 17%, low 40% 16%. At least one detected 81% patients; most frequent were SF3B1...
This JAMA Oncology Patient Page discusses classification of breast cancer and ERBB2 status.
Physician workforce diversity can be a driver of institutional excellence, improving innovation and reducing health disparities. However, the current hematology/oncology (HO) does not reflect that US population.
The treatment of metastatic prostate cancer has been revolutionized with the advent many targeted therapies, including immunotherapy. Pembrolizumab demonstrated benefit in certain patients docetaxel-refractory castrate-resistant (mCRPC). However, extrapolation these data to HIV is limited, as are conventionally excluded from therapeutic clinical trials. This study aims develop a better understanding outcomes positive treated A review literature conducted on use immunotherapy cancer, and...
Prime childbearing years occur during medical training and early career, leaving physicians with tough choices between family planning career growth. Restrictive workplace parental leave (PL) policies may negatively affect physician well-being. We evaluate existing PL lactation policies, as well return-to-work experiences, among oncology trainees early-career faculty.An anonymous 43-question cross-sectional survey was distributed via e-mail social media channels May June 2021 to within 5 of...
11054 Background: Training and early career years coincide with childbearing raising young families, which places increased demands on new parents. With increasing numbers of female oncologists in the workforce, there is a need to assess amend current workplace lactation policies. We surveyed Medical Radiation Oncology trainees faculty policies practices regarding during training career. Methods: An anonymous 48 question cross-sectional survey developed by researchers expertise gender equity...
Abstract Introduction: Interstitial Lung Disease (ILD) is a known adverse event associated with Antibody Drug Conjugates (ADCs), causing fibrosis of the lung. In DESTINY-Breast 04, TROPICS-02, and ASCENT trials rate ILD/Pneumonitis was 12.1%, 0.4%, 0% respectively. these studies, time to first cross-sectional imaging after initiation ADC 6 weeks. However, prior treatment topoisomerase-1 inhibitor not permitted in so influence sequential treatments remains unknown. Here, we aimed characterize...
e24129 Background: Aromatase inhibitors (AIs) are commonly used for postmenopausal women with hormone receptor positive breast cancer. Nearly 2 of 3 on AIs complain AIMSS leading to poor adherence. Preclinical and clinical pilot data suggest topical cannabinoids can reduce inflammation in arthritis. Methods: We conducted a randomized controlled trial assessing the feasibility acceptability two different medical cannabis balms AIMSS. Women stage 1-3 cancer [scoring 4 or higher at least one...
Abstract Background: The COVID-19 pandemic and associated shutdowns disrupted healthcare access resulted in decreased cancer screenings. Cancer diagnosis delays have concerning downstream effects on late-stage cancer, especially for marginalized populations. Methods: study population included 349,458 adults the California Registry diagnosed with between January 2019 December 2021, during which experienced two stay-at-home orders. We examined percentage of (III–IV) diagnoses across five...